Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors show survival benefits in ovarian cancer patients with BRCA1/2 mutation or homologous recombination (HR) deficiency, but only limited efficacy in HR-proficient ones. Another drug, arsenic trioxide (ATO) or arsenic drug (RIF), exerts...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junfen, Shen, Yuanming, Wang, Conghui, Tang, Sangsang, Hong, Shiyuan, Lu, Weiguo, Xie, Xing, Cheng, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458481/
https://www.ncbi.nlm.nih.gov/pubmed/34552062
http://dx.doi.org/10.1038/s41420-021-00638-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458481/
https://www.ncbi.nlm.nih.gov/pubmed/34552062
http://dx.doi.org/10.1038/s41420-021-00638-2

Ejemplares similares